BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.
The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.
BridgeBio has historically faced challenges in developing pipeline candidates and bringing them to market.
|
Metric
|
BBIO
|
ALNY
|
BNTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 43.63 | — |
Price/Book Value | — | 35.14 | 1.08 |
Price/Sales | 26.68 | 9.04 | 6.90 |
Price/Cash Flow | — | 31.28 | — |
|
Metric
|
BBIO
|
ALNY
|
BNTX
|
|---|---|---|---|
Quick Ratio | 1.40 | 2.88 | 8.64 |
Current Ratio | 1.52 | 3.13 | 8.80 |
Interest Coverage | −2.97 | 2.68 | — |
|
Metric
|
BBIO
|
ALNY
|
BNTX
|
|---|---|---|---|
Return on Assets (Normalized) | −55.55% | 18.61% | −3.94% |
Return on Equity (Normalized) | — | 179.16% | −4.50% |
Return on Invested Capital (Normalized) | −848.32% | 59.07% | −4.61% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|g?>?sHC | LOCK|<D$x | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#dt^#?% | LOCK|&#wN | $70B | |||
| argenx SE ADR
ARGX
| LOCK|>GrlbM | LOCK|Jsy | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|V@@Fnx | LOCK|<Bz&! | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GcVyB! | LOCK|$&J | $37B | |||
| Moderna Inc
MRNA
| LOCK|!M?P&t | LOCK|@%& | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|><M@?gw | LOCK|>H>$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|sqC&>X$ | LOCK|r$ | $23B | |||
| Incyte Corp
INCY
| LOCK|c!yh^?c | LOCK|%g | $23B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
United States